Better Peptide Company is pioneering the first rigorous clinical research program for BPC-157 — a naturally occurring peptide with compelling preclinical evidence across gastrointestinal healing, musculoskeletal repair, and neuroprotection. We are building the scientific foundation to bring this compound through formal human trials.
Investigating BPC-157's role in mucosal healing, gut permeability, and inflammatory bowel conditions — areas with significant unmet clinical need.
Studying accelerated tendon, ligament, and bone healing mechanisms — building on extensive preclinical data showing consistent regenerative effects.
Exploring BPC-157's neuroprotective and neurogenic properties, including potential applications in traumatic brain injury and neurodegenerative conditions.
Establishing a rigorous human safety profile through structured Phase I trial design — the foundational step toward regulatory approval.
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein found in human gastric juice. First isolated and studied in the 1990s, it has accumulated a substantial body of animal research demonstrating a remarkably broad therapeutic profile.
Despite widespread use in research and performance communities, BPC-157 has never been taken through a formal human clinical trial. Better Peptide Company exists to close that gap — with rigorous methodology, regulatory engagement, and scientific transparency.
Whether you're a researcher, clinician, investor, or potential trial participant — we want to hear from you. We're actively building our network of collaborators and advisors.